导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.38% | 1412/4773 |
| 近一周 | -1.98% | 3223/5465 |
| 近一月 | -2.66% | 1805/5421 |
| 近一季 | -4.26% | 1774/5231 |
| 近半年 | 1.72% | 1136/4920 |
| 近一年 | 9.21% | 1227/4394 |
| 近两年 | 59.34% | 1257/2954 |
| 近三年 | 36.16% | 870/2253 |
| 成立以来 | 59.96% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.09% 2673/4961 |
13.32% 2029/5312 |
- - |
- - |
| 2025 | 27.55% 1552/4813 |
-1.60% 2707/3635 |
4.33% 792/4076 |
21.92% 1733/4524 |
1.92% 1154/4813 |
| 2024 | 12.07% 1276/3463 |
4.72% 435/2808 |
-2.31% 1173/3014 |
13.90% 2078/3129 |
-3.82% 2390/3463 |
| 2023 | -15.08% 1637/2656 |
2.25% 1389/2280 |
-4.95% 1325/2385 |
-4.85% 1239/2515 |
-8.18% 2259/2655 |
| 2022 | -18.36% 700/2207 |
-12.53% 627/1919 |
9.11% 298/2016 |
-12.74% 773/2113 |
-1.98% 1765/2208 |
| 2021 | 1.11% 691/1822 |
-2.05% 573/1255 |
4.25% 907/1330 |
-1.49% 527/1466 |
0.51% 1096/1822 |
| 2020 | 39.44% 332/1250 |
-5.86% 441/1028 |
15.58% 485/1067 |
14.88% 251/1164 |
11.55% 534/1184 |
| 2019 | - - |
- - |
- - |
- - |
7.87% 386/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 申万菱信沪深300指数增强C VS. 长安沪深300非周期A(740101) |